ANDA 76523, held by Hikma. Mefloquine Hydrochloride.
As of Nov 16, 2026, ANDA 76523 (Mefloquine Hydrochloride), held by Hikma, was first approved by FDA on Oct 1, 2004, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 1, 2004 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Mefloquine Hydrochloride250MG · tablet;oral | Mefloquine Hydrochloride | Discontinued |
| Oct 11, 2016 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 26, 2013 | Supplement 7Labeling · Standard review | Approved | |
| Aug 15, 2011 | Supplement 6Labeling | Approved | None posted |
| Nov 18, 2009 | Supplement 5Labeling | Approved | None posted |
| Oct 20, 2009 | Supplement 4Labeling | Approved | None posted |
| Feb 19, 2009 | Supplement 3Labeling | Approved | None posted |
| Sep 18, 2008 | Supplement 2Labeling | Approved | None posted |
| Oct 1, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters